TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15712100

Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg iv q24h)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500-1000 mg iv q6-8h)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 222

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Levofloxacin and Imipenem-cilastatin
Number of subjects: 222
Study: 11902617

Group type: EXPERIMENTAL
Intervention: Participants who discovered disagreement with the Black person after 12 minutes of observation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who discovered agreement with the Black person after 12 minutes of observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants who disagreed with the Black person
Number of subjects: 0
Study: 9932953

Group type: COMPARATOR
Intervention: Male patients with PNH
Number of subjects: 17

Group type: COMPARATOR
Intervention: Female patients with PNH
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 17
Study: 7598139

Group type: EXPERIMENTAL
Intervention: Step-One diet plus continuous combined hormone-replacement therapy (conjugated estrogens 0.625 mg/d plus medroxyprogesterone 2.5 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Step-One diet plus placebo
Number of subjects: 32
Study: 2222986

Group type: EXPERIMENTAL
Intervention: 40 mg/day of baclofen
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 80 mg/day of baclofen
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 870547

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31190490

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with venlafaxine hydrochloride (75 mg/day in 1st week, 150 mg/day in 2nd week, 225 mg/day from 3rd to 6th week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Venlafaxine hydrochloride (75 mg/day in 1st week, 150 mg/day in 2nd week, 225 mg/day from 3rd to 6th week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy volunteers (normal group)
Number of subjects: 60
Study: 28259608

Group type: EXPERIMENTAL
Intervention: Busulfan and melphalan
Number of subjects: 598

Group type: COMPARATOR
Intervention: Carboplatin, etoposide, and melphalan
Number of subjects: 598
Study: 26553894

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including academic detailing, web-based treatment algorithms, and tailored patient information leaflets
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care with simple patient-level PIP feedback
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study: 24009416

Group type: EXPERIMENTAL
Intervention: Aquatic group (AG)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Land group (LG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study: 21906314

Group type: EXPERIMENTAL
Intervention: Chlorella-derived multicomponent supplement (30 tablets per day for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (30 tablets per day for 4 weeks)
Number of subjects: 15
Study: 18495676

Group type: EXPERIMENTAL
Intervention: E-learning educational session
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lecture-based learning educational session
Number of subjects: 74
Study: 16539560

Group type: EXPERIMENTAL
Intervention: Light curing the primer before contamination with blood or saliva
Number of subjects: 180

Group type: COMPARATOR
Intervention: No light curing of the primer before contamination with blood or saliva
Number of subjects: 180
Study: 12649401

Group type: EXPERIMENTAL
Intervention: Chimeric anti-TNFalpha antibodies (3 mg/kg, bimonthly i.v.)
Number of subjects: 15
Study: 10976558

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus mitomycin C (MMC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) only
Number of subjects: 8
Study: 9174227

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy combined with a healthy-eating lifestyle program
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (54 obese school children)
Number of subjects: 205
Study: 8055999

Group type: EXPERIMENTAL
Intervention: Oral captopril
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Oral isosorbide mononitrate
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 874

Group type: COMPARATOR
Intervention: Control
Number of subjects: 874
Study: 2648642

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment, 150 mg twice daily for four weeks
Number of subjects: 48
Study: 4553942

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical exertion
Number of subjects: 0
Study: 31885802

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Continuous Exercise (CE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 13
Study: 28741425

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 25987833

Group type: EXPERIMENTAL
Intervention: Generic clopidogrel bisulfate 75 mg film‐coated tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plavix® clopidogrel bisulfate 75 mg film‐coated tablets
Number of subjects: 0
Study: 23143849

Group type: EXPERIMENTAL
Intervention: Obese males
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Obese females
Number of subjects: 306

Group type: COMPARATOR
Intervention: BMI >95th percentile (regardless of sex)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sex interaction with obesity
Number of subjects: 306
Study: 21459381

Group type: EXPERIMENTAL
Intervention: Multidimensional exercise treatment (twice a week for 3 months)
Number of subjects: 127
Study: 19105212

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (HFL‐rTMS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (LFR‐rTMS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both HFL‐rTMS and LFR‐rTMS
Number of subjects: 27
Study: 17598007

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) - 5,000 IU iv bolus followed by 450 IU/kg/24 h for 72 hours (n = 7)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; dalteparin) - 200 IU/kg sc once daily for 72 hours (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; dalteparin) - 100 IU/kg sc once (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) - 250 IU/kg sc once (n = 7)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control - saline infusion for 12 hours (n = 7)
Number of subjects: 22
Study: 15281515

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 150
Study: 11531036

Group type: EXPERIMENTAL
Intervention: Reparil‐Gel N (n = 32)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reparil‐Gel (n = 31)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reparil‐Sportgel (n = 32)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo gel (n = 31)
Number of subjects: 126
Study: 8816121

Group type: EXPERIMENTAL
Intervention: Time Out! For Me (experimental group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 1460184

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (75 mg Zn/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (75 mg Zn/day) in bulimics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo in bulimics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (75 mg Zn/day) in anorexics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo in anorexics
Number of subjects: 33
Study: 2866965

Group type: EXPERIMENTAL
Intervention: bopindolol 1.35 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: metoprolol 144 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg o.d. and 8 mg once weekly
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: bopindolol long-term therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: bopindolol treatment withdrawal
Number of subjects: 14
Study: 30755452

Group type: EXPERIMENTAL
Intervention: Imarikiren 5 mg
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Imarikiren 20 mg
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Imarikiren 40 mg
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 29412077

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 48
Study: 26547304

Group type: EXPERIMENTAL
Intervention: When Cancer Calls… (WCC…) video
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Control video on cancer nutrition and diet
Number of subjects: 1006
Study: 25455834

Group type: EXPERIMENTAL
Intervention: Chiropractic intervention (specific details not provided)
Number of subjects: 247
Study: 22595104

Group type: EXPERIMENTAL
Intervention: Platelet concentrate applied during endodontic surgery (in liquid form on the root end, in clot form within the bone defect, and in liquid form over the suture).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (modern endodontic surgical procedure without platelet concentrate).
Number of subjects: 36
Study: 19195850

Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Group sessions on depression prevention
Number of subjects: 410

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Baseline BDI
Number of subjects: 410
Study: 17487767

Group type: EXPERIMENTAL
Intervention: On-pump surgery (with CPB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Off-pump surgery (without CPB)
Number of subjects: 34
Study: 14694250

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP) treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Discontinuation of CPAP treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 11581607

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 9836209

Group type: EXPERIMENTAL
Intervention: Midazolam 0.25 mg.kg‐1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Midazolam 0.75 mg.kg‐1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1 and 0.75 mg.kg‐1
Number of subjects: 102
Study: 8120268

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 240

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 240
Study: 2223156

Group type: EXPERIMENTAL
Intervention: Bestatin combination therapy (30 mg daily)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 526384

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 2 mg/kg body weight
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ergometrine 0.5 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: intra-cervical 0.5% lignocaine 20 ml
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: sodium thiopentone 4 mg/kg body weight
Number of subjects: 37

Group type: COMPARATOR
Intervention: sodium thiopentone
Number of subjects: 37

Group type: COMPARATOR
Intervention: i.v. ketamine
Number of subjects: 37
Study: 30894455

Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (0.01-20 mg/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (5 or 10 mg/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lacnotuzumab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28280233

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Ceramide score (weighted sum of concentrations of four ceramides)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of C16:0, C22:0, C24:0, and C24:1 ceramides
Number of subjects: 980
Study: 25826373

Group type: EXPERIMENTAL
Intervention: unfermented whole grain rye crisp bread (uRCB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: fermented whole grain rye crisp bread (RCB)
Number of subjects: 23

Group type: COMPARATOR
Intervention: refined wheat crisp bread (WCB)
Number of subjects: 23
Study: 23383171

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pre-ART
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Post-ART
Number of subjects: 96
Study: 22177431

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 64
Study: 19961377

Group type: EXPERIMENTAL
Intervention: Microthreads placed at the implant top (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microthreads placed 0.5 mm below the implant top (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of bone loss between groups A and B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gingival parameters (modified plaque index and modified sulcus bleeding index)
Number of subjects: 20
Study: 17085674

Group type: EXPERIMENTAL
Intervention: Aspirin intervention
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Variant UGT1A6 alleles
Number of subjects: 546
Study: 15101466

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 11733800

Group type: EXPERIMENTAL
Intervention: Intermittent crossclamping of the aorta with ischemic preconditioning (2 crossclampings of 3min each with 2min reperfusion)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intermittent crossclamping of the aorta without ischemic preconditioning (control group)
Number of subjects: 35
Study: 9310536

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 262
Study: 7667706

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unimmunized children
Number of subjects: 0
Study: 3540212

Group type: EXPERIMENTAL
Intervention: Acyclovir, 45 mg/kg/day as a continuous IV infusion for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No other therapy (Control)
Number of subjects: 30
Study: 28823180

Group type: EXPERIMENTAL
Intervention: Problem solving in controllable condition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Rumination in controllable condition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Rumination in uncontrollable condition
Number of subjects: 128

Group type: COMPARATOR
Intervention: Problem solving in uncontrollable condition
Number of subjects: 128
Study: 28579385

Group type: EXPERIMENTAL
Intervention: TiF4 varnish
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NaF varnish
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 20
Study: 26605707

Group type: EXPERIMENTAL
Intervention: Secured email message
Number of subjects: 14584

Group type: EXPERIMENTAL
Intervention: Mailed letter
Number of subjects: 14584

Group type: EXPERIMENTAL
Intervention: Telephone message
Number of subjects: 14584

Group type: COMPARATOR
Intervention: Usual-care arm (no outreach)
Number of subjects: 14584
Study: 22533576

Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 891

Group type: COMPARATOR
Intervention: Standard-dose CT
Number of subjects: 891
Study: 19846273

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18468871

Group type: EXPERIMENTAL
Intervention: ANFIS trained with PCA; classification results: 96.87%, 98.43%, 98.43%.
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: ANFIS combined with weighted arithmetical mean; classification results: 98.43%, 100%, 100%.
Number of subjects: 129

Group type: COMPARATOR
Intervention: ANN ensemble; classification results: 98.43%, 100%, 100%.
Number of subjects: 129
Study: 15666120

Group type: EXPERIMENTAL
Intervention: Low-dose etidronate (200 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-dose etidronate (400 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment with osteoactive drugs)
Number of subjects: 44
Study: 12897639

Group type: EXPERIMENTAL
Intervention: Selegiline 15 mg/day for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10526278

Group type: EXPERIMENTAL
Intervention: rGM-CSF
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chemotherapy (idarubicin, methylprednisolone, high dose ara-C)
Number of subjects: 67
Study: 8682147

Group type: EXPERIMENTAL
Intervention: 10 ml kg‐1 of Ringer acetate solution without glucose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 ml kg‐1 of Ringer acetate solution with 0.5% glucose
Number of subjects: 40
Study: 1880475

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6295132

Group type: EXPERIMENTAL
Intervention: Exercise training (4 mile walk‐jog run program 3 times weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wheat bran feeding (0.5 g/kg body weight)
Number of subjects: 20
Study: 30900607

Group type: EXPERIMENTAL
Intervention: 10 mL
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 100 mL
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 150 mL
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 200 mL
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 250 mL
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 300 mL
Number of subjects: 123
Study: 29031935

Group type: EXPERIMENTAL
Intervention: 4-h face-to-face RESPECT mental health training programme
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Deferred training control group
Number of subjects: 1966
Study: 25638718

Group type: EXPERIMENTAL
Intervention: Immediate access to feed (0 h)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Delayed access to feed (24 h)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Delayed access to feed (6 h)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Delayed access to feed (12 h)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Overall oocyst shedding
Number of subjects: 480
Study: 24327421

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stents (EES)
Number of subjects: 2853
Study: 23008509

Group type: EXPERIMENTAL
Intervention: LAA closure with the Watchman device
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Sustained anticoagulation (warfarin)
Number of subjects: 1273
Study: 21029995

Group type: EXPERIMENTAL
Intervention: HighCPAP treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: LowCPAP treatment
Number of subjects: 11
Study: 17512011

Group type: EXPERIMENTAL
Intervention: Buspirone HCl 30 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15775926

Group type: EXPERIMENTAL
Intervention: Silica coating using Rocatec System (Group RS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Silica coating using CoJet System (Group CS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Airborne-particle abrasion with 110-microm Al2O3 (Group SB)
Number of subjects: 15
Study: 12063520

Group type: COMPARATOR
Intervention: HFA-BDP (200 microg twice daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: FP-SM (100 microg FP and 50 microg SM twice daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: DPI-BDP (1000 microg twice daily for 4 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: DPI-BDP
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: FP-SM and HFA-BDP
Number of subjects: 39
Study: 9877478

Group type: EXPERIMENTAL
Intervention: Liquid oxygen (L)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Concentrator (C/C)
Number of subjects: 51
Study: 7634630

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intraoperatively and 30 mg every 8 hours for 5 doses postoperatively
Number of subjects: 303

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 303
Study: 2224948

Group type: EXPERIMENTAL
Intervention: Aspirin plus Nicardipine (250 mg of aspirin once daily plus 20 mg of nicardipine thrice daily, n = 170)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Aspirin only (250 mg of aspirin once daily, n = 94)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Aspirin plus Nicardipine
Number of subjects: 264

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 264